早期状非小细胞肺癌中的PI3K/mTORC2-RICTOR轴:基因组学,分子表达和临床相关性
Sara Pilotto1, Lorenzo Belluomini1, Federico Monaca2,3
1Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy.
Therapeutic advances in medical oncology
|November 12, 2025
概括
对切除的状非小细胞肺癌 (状NSCLC) 的基因组分析确定PI3KCA/mTOR途径是关键因素. 这种途径的变化,包括突变和拷贝数的变化,与患者的预后相关.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 对切除状非小细胞肺癌 (状NSCLC) 的预后因素和改变途径的有限理解.
- 需要进行全面的基因组分析,以确定状NSCLC预后的分子驱动因素.
研究的目的:
- 分析状NSCLC的预后异常患者的基因组背景.
- 评估差异基因组学及其与患者预后的关系.
- 确定分子变化和影响切除状NSCLC生存的途径.
主要方法:
- 对三个状NSCLC队列的回顾性研究.
- 下一代测序 (NGS) 用于体突变和副本数变异 (CNVs).
- 纳米链表达分析用于评估基因表达模式.
主要成果:
- 副本数变异 (CNVs) 是最常见的基因组事件.
- PI3KCA/mTOR通路的改变 (42%) 是最常见的,特定突变 (PI3KCA) 和增益 (RICTOR) 与预后不佳有关.
- 在预后良好的患者中观察到PI3K/AKT/mTOR通路的下调.
结论:
- PI3KCA/mTOR途径在状NSCLC的瘤发生和预后中发挥着重要作用.
- 基因组异常和PI3KCA/mTOR途径的改变表达影响了切除状NSCLC患者的存活率.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
14.3K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
